Cytosorbents (CTSO) Tops Q4 EPS by 2c, Misses on Revenue

Cytosorbents (NASDAQ: CTSO) reported Q4 EPS of ($0.03), $0.02 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $9.15 million versus the consensus estimate of $10.25 million.

For earnings history and earnings-related data on Cytosorbents (CTSO) click here.

You May Also Be Interested In

• FDA Committee Recommends To Widen Access To Bpc-157 Peptide
• Origin Bancorp, Inc. (OBK) Tops Q2 EPS by 9c
• Bleecker Street Research is short Lyft (LYFT)